Ovid Therapeutics Inc.OVIDEarnings & Financial Report
Nasdaq
OVID Q3 2025 Key Financial Metrics
Revenue
$132.0K
Gross Profit
N/A
Operating Profit
$-12.5M
Net Profit
$-12.2M
Gross Margin
N/A
Operating Margin
-9487.1%
Net Margin
-9210.6%
YoY Growth
-23.7%
Financial Flow
Ovid Therapeutics Inc. Q3 2025 Financial Summary
Ovid Therapeutics Inc. reported revenue of $132.0K for Q3 2025, with a net profit of $-12.2M (-9210.6% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $132.0K |
|---|---|
| Net Profit | $-12.2M |
| Gross Margin | N/A |
| Operating Margin | -9487.1% |
| Report Period | Q3 2025 |
Ovid Therapeutics Inc. Annual Revenue by Year
Ovid Therapeutics Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $566.0K).
| Year | Annual Revenue |
|---|---|
| 2024 | $566.0K |
| 2023 | $391.7K |
| 2022 | $1.5M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $141563 | $148000 | $169000 | $173000 | $76000 | $130000 | $6.3M | $132000 |
| YoY Growth | 205.9% | 123.7% | 125.3% | 58.8% | -46.3% | -12.2% | 3611.2% | -23.7% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $144.0M | $131.6M | $118.1M | $102.7M | $92.2M | $81.7M | $77.4M | $63.8M |
| Liabilities | $56.2M | $53.3M | $29.2M | $26.4M | $23.9M | $22.4M | $21.6M | $19.1M |
| Equity | $87.8M | $78.3M | $88.9M | $76.3M | $68.2M | $59.3M | $55.8M | $44.7M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-11.9M | $-16.7M | $-14.3M | $-15.0M | $-10.0M | $-10.3M | $-4.8M | $-12.9M |